 Lays Martin Sobral
Concepts (199)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 7 | 2020 | 70 | 1.380 |
Why?
| | Carcinoma, Squamous Cell | 10 | 2020 | 577 | 1.260 |
Why?
| | Histone Chaperones | 5 | 2020 | 13 | 1.150 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 2 | 2020 | 60 | 0.780 |
Why?
| | Fibroblasts | 9 | 2011 | 834 | 0.680 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 347 | 0.520 |
Why?
| | Antineoplastic Agents | 5 | 2020 | 1875 | 0.460 |
Why?
| | Cell Proliferation | 10 | 2020 | 2173 | 0.430 |
Why?
| | Head and Neck Neoplasms | 3 | 2017 | 427 | 0.420 |
Why?
| | Myofibroblasts | 3 | 2011 | 115 | 0.420 |
Why?
| | Transcription Factors | 3 | 2017 | 1526 | 0.410 |
Why?
| | DNA-Binding Proteins | 5 | 2020 | 1311 | 0.380 |
Why?
| | Gingiva | 4 | 2011 | 22 | 0.350 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 29 | 0.340 |
Why?
| | Peptides | 2 | 2020 | 847 | 0.340 |
Why?
| | Stromal Cells | 5 | 2011 | 96 | 0.330 |
Why?
| | Activins | 2 | 2015 | 26 | 0.320 |
Why?
| | MicroRNAs | 2 | 2020 | 600 | 0.300 |
Why?
| | Smad7 Protein | 3 | 2011 | 18 | 0.300 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2020 | 1145 | 0.290 |
Why?
| | Mouth Mucosa | 3 | 2017 | 79 | 0.280 |
Why?
| | Gingival Overgrowth | 2 | 2011 | 5 | 0.280 |
Why?
| | Cyclosporine | 2 | 2011 | 161 | 0.260 |
Why?
| | Keratinocytes | 1 | 2017 | 215 | 0.260 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 518 | 0.250 |
Why?
| | Matrix Metalloproteinase 2 | 3 | 2011 | 56 | 0.250 |
Why?
| | Neoplasms | 1 | 2019 | 2086 | 0.250 |
Why?
| | Histones | 1 | 2020 | 529 | 0.250 |
Why?
| | Cell Survival | 6 | 2020 | 1014 | 0.240 |
Why?
| | Doxorubicin | 1 | 2015 | 286 | 0.230 |
Why?
| | Transforming Growth Factor beta1 | 5 | 2011 | 153 | 0.230 |
Why?
| | Mice, Nude | 4 | 2020 | 628 | 0.230 |
Why?
| | Matrix Metalloproteinases | 2 | 2011 | 89 | 0.220 |
Why?
| | Cell Transdifferentiation | 3 | 2010 | 31 | 0.210 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2014 | 167 | 0.200 |
Why?
| | Lipids | 1 | 2015 | 564 | 0.200 |
Why?
| | Nanoparticles | 1 | 2015 | 312 | 0.190 |
Why?
| | Skin | 1 | 2015 | 653 | 0.190 |
Why?
| | PAX3 Transcription Factor | 1 | 2020 | 12 | 0.180 |
Why?
| | Connective Tissue Growth Factor | 5 | 2017 | 21 | 0.180 |
Why?
| | Neoplasm Invasiveness | 5 | 2017 | 438 | 0.180 |
Why?
| | Forkhead Box Protein O1 | 1 | 2020 | 15 | 0.180 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2020 | 12 | 0.180 |
Why?
| | Proto-Oncogene Protein c-ets-1 | 1 | 2020 | 19 | 0.180 |
Why?
| | Mice, Inbred BALB C | 3 | 2020 | 1144 | 0.170 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 695 | 0.170 |
Why?
| | Rhabdomyosarcoma | 1 | 2020 | 56 | 0.170 |
Why?
| | Cell Line, Tumor | 5 | 2020 | 2700 | 0.170 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2014 | 636 | 0.170 |
Why?
| | Ameloblastoma | 1 | 2008 | 5 | 0.160 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2020 | 179 | 0.150 |
Why?
| | Skin Neoplasms | 1 | 2015 | 754 | 0.150 |
Why?
| | Dihydropyridines | 1 | 2017 | 15 | 0.150 |
Why?
| | Tongue Neoplasms | 1 | 2007 | 20 | 0.150 |
Why?
| | Blotting, Western | 5 | 2017 | 1143 | 0.140 |
Why?
| | Angiogenesis Inducing Agents | 1 | 2017 | 21 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 367 | 0.140 |
Why?
| | Annexin A1 | 1 | 2017 | 2 | 0.140 |
Why?
| | Paracrine Communication | 1 | 2007 | 55 | 0.140 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2017 | 56 | 0.140 |
Why?
| | Fibromatosis, Gingival | 2 | 2007 | 2 | 0.140 |
Why?
| | Bone Neoplasms | 1 | 2008 | 191 | 0.130 |
Why?
| | Retinal Pigment Epithelium | 1 | 2017 | 58 | 0.130 |
Why?
| | Transforming Growth Factor beta | 2 | 2007 | 445 | 0.130 |
Why?
| | Cell Line | 3 | 2020 | 2629 | 0.130 |
Why?
| | Neovascularization, Physiologic | 1 | 2017 | 174 | 0.130 |
Why?
| | Animals | 9 | 2020 | 31565 | 0.130 |
Why?
| | RNA, Neoplasm | 1 | 2015 | 80 | 0.120 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 307 | 0.120 |
Why?
| | Humans | 23 | 2020 | 114045 | 0.120 |
Why?
| | Phenotype | 4 | 2020 | 2784 | 0.120 |
Why?
| | Multigene Family | 1 | 2015 | 190 | 0.120 |
Why?
| | Actins | 5 | 2011 | 376 | 0.120 |
Why?
| | Gene Knockdown Techniques | 3 | 2020 | 301 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2017 | 924 | 0.120 |
Why?
| | Adipose Tissue | 1 | 2017 | 545 | 0.110 |
Why?
| | Down-Regulation | 4 | 2017 | 594 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 787 | 0.110 |
Why?
| | Lymphatic Metastasis | 3 | 2015 | 275 | 0.110 |
Why?
| | Apoptosis | 5 | 2017 | 2349 | 0.110 |
Why?
| | Cofilin 1 | 1 | 2012 | 5 | 0.110 |
Why?
| | Cell Movement | 1 | 2017 | 863 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1356 | 0.100 |
Why?
| | Neoplasm Proteins | 1 | 2015 | 385 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2014 | 314 | 0.100 |
Why?
| | Muscle, Smooth | 3 | 2011 | 142 | 0.100 |
Why?
| | Mice | 6 | 2020 | 14843 | 0.090 |
Why?
| | Protein Phosphatase 2 | 1 | 2020 | 30 | 0.090 |
Why?
| | Retinoblastoma Protein | 1 | 2020 | 52 | 0.090 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 80 | 0.080 |
Why?
| | Ki-67 Antigen | 1 | 2020 | 102 | 0.080 |
Why?
| | Drug Synergism | 1 | 2020 | 315 | 0.080 |
Why?
| | Methylation | 1 | 2020 | 208 | 0.080 |
Why?
| | Cell Differentiation | 3 | 2020 | 1696 | 0.080 |
Why?
| | Gene Expression | 2 | 2017 | 1417 | 0.070 |
Why?
| | Immunohistochemistry | 3 | 2012 | 1624 | 0.070 |
Why?
| | Phosphorylation | 2 | 2012 | 1558 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2011 | 845 | 0.070 |
Why?
| | Up-Regulation | 2 | 2017 | 802 | 0.070 |
Why?
| | Mitochondrial Dynamics | 1 | 2017 | 22 | 0.070 |
Why?
| | Smad2 Protein | 2 | 2011 | 33 | 0.070 |
Why?
| | Proteomics | 1 | 2012 | 815 | 0.070 |
Why?
| | Cell Cycle | 2 | 2017 | 541 | 0.070 |
Why?
| | NF-kappa B | 1 | 2020 | 636 | 0.070 |
Why?
| | Disease-Free Survival | 2 | 2020 | 618 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2010 | 641 | 0.060 |
Why?
| | Carcinogenesis | 1 | 2017 | 175 | 0.060 |
Why?
| | Skin Absorption | 1 | 2015 | 11 | 0.060 |
Why?
| | Iontophoresis | 1 | 2015 | 13 | 0.060 |
Why?
| | Male | 9 | 2020 | 55396 | 0.060 |
Why?
| | Collagen Type I | 2 | 2011 | 108 | 0.060 |
Why?
| | Administration, Topical | 1 | 2015 | 137 | 0.060 |
Why?
| | Cell Culture Techniques | 2 | 2011 | 341 | 0.060 |
Why?
| | Culture Media | 2 | 2017 | 155 | 0.060 |
Why?
| | Interferon-gamma | 1 | 2007 | 719 | 0.050 |
Why?
| | Child | 2 | 2019 | 18401 | 0.050 |
Why?
| | Swine | 1 | 2015 | 687 | 0.050 |
Why?
| | Necrosis | 1 | 2014 | 209 | 0.050 |
Why?
| | Fluorescent Antibody Technique | 1 | 2014 | 396 | 0.050 |
Why?
| | NM23 Nucleoside Diphosphate Kinases | 1 | 2012 | 2 | 0.050 |
Why?
| | Fluorometry | 1 | 2012 | 19 | 0.050 |
Why?
| | Cisplatin | 1 | 2014 | 262 | 0.050 |
Why?
| | DNA Fragmentation | 1 | 2012 | 47 | 0.050 |
Why?
| | Aged | 5 | 2020 | 18969 | 0.050 |
Why?
| | Caspase 9 | 1 | 2012 | 48 | 0.050 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2012 | 87 | 0.050 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2012 | 40 | 0.050 |
Why?
| | Organelles | 1 | 2012 | 51 | 0.050 |
Why?
| | Immunoassay | 1 | 2012 | 95 | 0.050 |
Why?
| | Antimetabolites | 1 | 2011 | 21 | 0.050 |
Why?
| | Adult | 6 | 2020 | 30375 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2011 | 72 | 0.050 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2011 | 69 | 0.050 |
Why?
| | Caspase 3 | 1 | 2012 | 234 | 0.050 |
Why?
| | Young Adult | 3 | 2020 | 10444 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 118 | 0.050 |
Why?
| | Glutathione | 1 | 2012 | 293 | 0.050 |
Why?
| | Female | 7 | 2020 | 59324 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1518 | 0.040 |
Why?
| | Prognosis | 2 | 2008 | 3315 | 0.040 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 192 | 0.040 |
Why?
| | Middle Aged | 5 | 2020 | 26605 | 0.040 |
Why?
| | Membrane Microdomains | 1 | 2020 | 31 | 0.040 |
Why?
| | Anthracyclines | 1 | 2020 | 42 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2012 | 397 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 292 | 0.040 |
Why?
| | Tretinoin | 1 | 2020 | 122 | 0.040 |
Why?
| | Enhancer Elements, Genetic | 1 | 2020 | 151 | 0.040 |
Why?
| | Transfection | 1 | 2011 | 863 | 0.040 |
Why?
| | Bone Marrow | 1 | 2020 | 243 | 0.040 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2008 | 28 | 0.040 |
Why?
| | Antioxidants | 1 | 2012 | 529 | 0.040 |
Why?
| | Mitochondrial Size | 1 | 2017 | 3 | 0.040 |
Why?
| | Cytoplasm | 1 | 2008 | 255 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2322 | 0.040 |
Why?
| | Extracellular Matrix | 1 | 2011 | 436 | 0.040 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2017 | 55 | 0.040 |
Why?
| | Genes, myc | 1 | 2017 | 46 | 0.040 |
Why?
| | Colony-Forming Units Assay | 1 | 2017 | 88 | 0.040 |
Why?
| | Tongue | 1 | 2007 | 66 | 0.040 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2017 | 37 | 0.040 |
Why?
| | Luciferases | 1 | 2017 | 142 | 0.040 |
Why?
| | Flow Cytometry | 1 | 2011 | 1075 | 0.040 |
Why?
| | Luminescent Measurements | 1 | 2017 | 74 | 0.030 |
Why?
| | Heterografts | 1 | 2017 | 117 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1206 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2017 | 88 | 0.030 |
Why?
| | Acyltransferases | 1 | 2017 | 46 | 0.030 |
Why?
| | Immediate-Early Proteins | 2 | 2007 | 52 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 2007 | 155 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2012 | 1068 | 0.030 |
Why?
| | Eye Diseases | 1 | 2017 | 74 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2020 | 1131 | 0.030 |
Why?
| | Neovascularization, Pathologic | 1 | 2017 | 280 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2011 | 784 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 229 | 0.030 |
Why?
| | Transcriptome | 1 | 2020 | 723 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 2 | 2007 | 347 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2015 | 206 | 0.030 |
Why?
| | Signal Transduction | 2 | 2011 | 4501 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1162 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 813 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2011 | 2550 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2017 | 445 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 99 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2008 | 1032 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 315 | 0.020 |
Why?
| | Disease Progression | 1 | 2008 | 2371 | 0.020 |
Why?
| | Adolescent | 2 | 2020 | 17800 | 0.020 |
Why?
| | Survival Rate | 1 | 2015 | 1638 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2012 | 622 | 0.020 |
Why?
| | Cytokines | 1 | 2017 | 1824 | 0.020 |
Why?
| | Collagen | 1 | 2010 | 414 | 0.020 |
Why?
| | Inflammation | 1 | 2017 | 2464 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2007 | 6306 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2020 | 12521 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2006 | 1218 | 0.010 |
Why?
| | Rats | 1 | 2010 | 4913 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2007 | 3861 | 0.010 |
Why?
|
|
Martin Sobral's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|